Startups

Shire

Shire is the historical UK-founded biopharmaceutical company founded in1986, formerly Shire plc, incorporated in Jersey and tax-resident in Ireland. Its pre-acquisition business focused on rare diseases and specialist therapies, including neuroscience and ADHD, hematology, immunology and genetic diseases. Akili’s own supporters page explicitly states that Shire Pharmaceuticals’ Strategic Investment group made a direct monetary investment in2013, separately from their collaboration on a pediatric ADHD clinical study; its check, precise date, financing stage and subscribing subsidiary are unpublished. Takeda completed the acquisition of all Shire shares on January8,2019. Shire’s independent stock listings ended; later2019 Takeda legal announcements call the subsidiary Shire Limited, formerly Shire plc. This record preserves the historical pharmaceutical buyer rather than retroactively assigning its2013 investment to Takeda or Takeda Ventures. Twenty published leaders in the2017 annual report’s early2018 board/executive directory are retained with historical and former roles, not claimed as a current independent Shire management team. Shire’s acquisitions, licensing commitments, revenue and manufacturing investments are distinct from venture-fund corpus. Actual2016 senior-note proceeds were issued by its separate financing subsidiary SAIIDAC; they are not a Shire venture fund or a duplicated parent fundraising event. Its own2017 annual report also explicitly reports an equity investment in Rani Therapeutics LLC, alongside a distinct December2017 research collaboration on oral FactorVIII delivery. The unpublished equity check is not inferred from licensing fees, options or commercial milestones; the full Rani issuer profile is queued separately.

Founded 1986